Future Oncology · 2022 · 15 citations · 8 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmunotherapy For Solid TumorsCheckpoint Inhibitor CombinationsCheckpoint Inhibitor TrialsCheckpoint Modulation In CancerCombination Checkpoint TherapyImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyRefractory Solid Tumors
AdAPT-001 is an investigational therapy consisting of a replicative type 5 adenovirus armed with a TGF-β receptor-immunoglobulin Fc fusion trap, designed to neutralize isoforms 1 and 3 of the profibrotic and immunosuppressive cytokine, TGF-β. In preclinical studies with an immunocompetent mouse model, AdAPT-001 eradicated directly treated ‘cold’ tumors as well as distant untreated tumors, and, from its induction of systemic CD8+ T cell-mediated antitumor immunity, protected the mice from rechallenge with tumor cells. AdAPT-001 also sensitized resistant tumors to checkpoint blockade. This manuscript describes the rationale and design of the first-in-human phase I, dose-escalation and dose-expansion study of AdAPT-001 alone and in combination with a checkpoint inhibitor in adults with treatment-refractory superficially accessible solid tumors.
8
2011: the immune hallmarks of cancer
Federica Cavallo, Carla De Giovanni, Patrizia Nanni et al. · Cancer Immunology Immunotherapy · 2011 · 416 citations · Full text
Medicine, Immunology, Oncology +17